首页|依达拉奉右莰醇联合丁苯酞对急性脑梗死溶栓后患者炎症反应及神经功能的影响

依达拉奉右莰醇联合丁苯酞对急性脑梗死溶栓后患者炎症反应及神经功能的影响

扫码查看
目的 探讨依达拉奉右莰醇联合丁苯酞对急性脑梗死溶栓后患者炎症反应、神经功能的影响.方法 选取2022年3月—2023年4月贵州省纳雍县人民医院收治的84例急性脑梗死患者为研究对象,按随机数表法分为两组,每组42例.对照组予以丁苯酞氯化钠注射液治疗,观察组在对照组基础上联合依达拉奉右莰醇治疗,两组均治疗2周.比较两组临床疗效、神经功能缺损、日常生活能力、炎性因子[白细胞介素-8(Inter-leukin-8,IL-8)、肿瘤坏死因子α(Tumor Necrosis Factor α,TNF-α)、超敏C反应蛋白(Hypersensitive C-reactive Protein,hs-CRP)]及不良反应发生率.结果 观察组总有效率(95.24%),高于对照组(80.95%),差异有统计学意义(x2=4.087,P<0.05);观察组治疗后Barthel指数评分为(79.47±6.04)分高于对照组,美国国立卫生研究院卒中量表评分(11.37±1.04)分、hs-CRP(8.03±1.82)mg/L、TNF-α(6.70±1.43)ng/L和IL-8(0.41±0.09)pg/mL水平均低于对照组,差异有统计学意义(P均<0.05).两组患者不良反应发生率比较,差异无统计学意义(P>0.05).结论 在急性脑梗死溶栓后患者中采用依达拉奉右莰醇+丁苯酞治疗可有效减轻神经功能损害、炎症反应,提高生活能力,且安全可靠.
Effects of Edaravone Dexborneol Combined with Butylphthalide on In-flammatory Response and Neurological Function in Patients after Throm-bolysis for Acute Cerebral Infarction
Objective To explore the effects of edaravone dexborneol combined with butylphthalide on inflammatory response and neurological function in patients after thrombolysis for acute cerebral infarction.Methods A total of 84 patients with acute cerebral infarction admitted to Guizhou Nayong County People's Hospital from March 2022 to April 2023 were selected as the study objects and divided into two groups according to random number table method,with 42 patients in each group.The control group was treated with butylphthalein sodium chloride injection,and the observation group was treated with Edaravone dextrocamphorol on the basis of the control group.Both groups were treated for 2 weeks.Comparison of clinical efficacy,neurological deficits,ability of daily living,inflammatory factors[interleukin-8(IL-8),tumor necrosis factor α(TNF-α),hypersensitive C-reactive protein(hs-CRP)],and the inci-dence of adverse reactions.Results The total effective rate of observation group was(95.24%)higher than that of con-trol group(80.95%),and the difference was statistically significant(x2=4.087,P<0.05).After treatment,the Barthel in-dex score of the observation group was(79.47±6.04),higher than that of the control group.The National Institutes of Health Stroke Scale score(11.37±1.04)points,hs-CRP(8.03±1.82)mg/L,TNF-α(6.70±1.43)ng/L and IL-8(0.41±0.09)pg/mL levels were all lower than those of the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The treatment with edaravone dexborneol + butylphthalide in post-thrombolysis patients with acute cere-bral infarction can effectively reduce neurological impairment,inflammatory response,improve the ability to live,and is safe and reliable.

Acute cerebral infarctionEdaravone dexborneolButylphthalideInflammatory responseNeurological functionAbility of daily living

黄薇、龙军

展开 >

贵州省纳雍县人民医院神经内科,贵州纳雍 553300

急性脑梗死 依达拉奉右莰醇 丁苯酞 炎症反应 神经功能 日常生活能力

2024

系统医学

系统医学

ISSN:
年,卷(期):2024.9(2)
  • 15